Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from enVVeno Medical ( (NVNO) ) is now available.
On December 11, 2025, enVVeno Medical Corporation held its Annual Meeting of Stockholders, where 54.70% of the voting power was represented. During the meeting, Matthew M. Jenusaitis and Robert A. Berman were elected as Class II directors, the compensation of named executive officers was approved on a non-binding basis, and CBIZ CPAs P.C. was ratified as the public accounting firm for 2025. However, the 2025 Equity Incentive Plan was not adopted, and the 2016 Omnibus Incentive Plan remains in effect. Additionally, the Board was granted authority to effectuate a reverse stock split at a ratio between one-for-five and one-for-thirty-five at their discretion.
Spark’s Take on NVNO Stock
According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.
enVVeno Medical’s overall stock score is influenced by its robust technical performance, which is somewhat overshadowed by challenging financial metrics. The company faces significant profitability issues, as reflected by its negative income and cash flow figures, despite having a stable balance sheet. While technical indicators show strong upward momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh on the score.
To see Spark’s full report on NVNO stock, click here.
More about enVVeno Medical
Average Trading Volume: 579,193
Technical Sentiment Signal: Sell
Current Market Cap: $7.02M
For an in-depth examination of NVNO stock, go to TipRanks’ Overview page.